Increased Use of Intensive Adjuvant Chemo in Stage I Breast Cancer
the Cancer Therapy Advisor take:
An increased use of intensive regimens by patients with stage I breast cancer was observed over time with significant institutional and cost variations, according to an article published online in the journal Cancer.
A common controversy for patients with stage I breast cancer is the uncertainty regarding the optimal threshold at which to consider chemotherapy, and if patients do choose to receive chemotherapy, they must then consider non-intensive versus intensive regimens.
The prospective cohort study involved patients treated at a National Comprehensive Cancer Network center from 2000 to 2009.
Each patient’s stage was defined according to the version of the American Joint Committee on Cancer Staging Manual that was being used at the time of diagnosis.
The patients were classified by human epidermal growth factor receptor 2 (HER2) status and then evaluated based on if they received non-intensive versus intensive adjuvant chemotherapy regimens.
Results showed that 33% of 8,907 patients with stage I breast cancer received a form of adjuvant chemotherapy. The number of patients with HER2-positive disease who received intensive regimens from 2000 to 2005 increased from 2008 to 2009 (31% to 63%, respectively).
Those patients with HER2-negative disease increased from 15% (2000 through 2005) to 41% (from 2008 to 2009). The regimens varied sufficiently across institutions along with cost variation (due to incorporation of biologics and growth factors).
An increased use of intensive regimens by patients with stage I breast cancer was observed over time.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer